Five VELDONA® Pet merchandise at the moment are available
New dietary supplements will launch in Taiwan in July forward of the deliberate worldwide launch, serving to to keep up immunity for thousands and thousands of pets
Ainos units its sights on coming into the $137 billion US pet market
SAN DIEGO, CA / ACCESSWIRE / June 14, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) (“Ainos”, or the “Company”), a diversified medtech firm centered on the event of novel point-of-care testing, low-dose interferon therapeutics, and artificial RNA-driven preventative medication, as we speak introduced the launch of two new VELDONA® Pet cytoprotein complement merchandise. VELDONA® Pet Shiny, formulated to help pets’ eye well being, and VELDONA® Pet Slim, designed to assist handle physique weight and weight-related well being points, will probably be launched subsequent month in Taiwan. The launch marks the ultimate step within the rollout of Ainos’ VELDONA® Pet product line. With all 5 merchandise launched efficiently, the Company is poised to push in direction of its aim of reaching US$20 million in gross sales from its VELDONA® Pet complement line throughout 2024.
VELDONA® Pet Shiny and VELDONA® Pet Slim bolster Ainos’ present line of VELDONA® Pet well being dietary supplements, which additionally consists of VELDONA® Pet Lohas for emotional wellbeing, VELDONA® Pet Soothing for relieving discomfort attributable to allergy symptoms, and VELDONA® Pet Cytoprotein complement for sustaining immunity, oral care, and gum and pores and skin well being. All VELDONA® Pet merchandise had been initially launched in Taiwan, with plans in place to begin advertising them throughout the globe within the close to future.
VELDONA® Pet Shiny offers aid for eye discomfort and helps the physique’s restoration from situations reminiscent of keratitis and ocular herpes infections. A examine carried out by Colorado State University indicated that interferon may cut back discomfort from eye infections and promotes therapeutic situations reminiscent of keratitis and eye herpes. VELDONA® Pet Shiny offers eye safety with out the potential drawbacks of conventional remedy strategies.
VELDONA® Pet Slim may help handle physique weight and handle metabolic imbalances arising from extra physique weight. Studies have demonstrated that interferon can inhibit diet-induced weight problems and mobile irritation related to weight problems. Supplementing with interferon reveals promise in managing physique weight and addressing metabolic imbalances ensuing from extra physique weight.
Chun-Hsien Tsai, Ainos’ Chairman of the Board, President, and Chief Executive Officer, commented, “The unveiling of our latest VELDONA® Pet dietary supplements showcases the substantial progress we now have made in reworking our business. In a number of brief months, we now have shifted from advertising COVID-19 check kits to establishing the muse we have to grow to be a very diversified and influential healthcare options supplier. These latest VELDONA® Pet merchandise are the following step in our evolution, however definitely aren’t the final.”
“As we broaden our portfolio and market our merchandise in areas throughout the globe, we draw nearer to our goal of reaching US$20 million in VELDONA® Pet complement gross sales in 2024,” Mr. Tsai added. “Our ultimate aim is to deliver VELDONA Pet to the U.S., the place complete pet expenditures exceeded $137 billion in 2022. The work we have put in by years of analysis and improvement is bearing fruit, and we anticipate the second half of 2023 will probably be an integral and thrilling time for our firm. I imagine Ainos is well-positioned for the following chapter of our story.”
About VELDONA® Pet
Based on Ainos’ low-dose oral interferon-alpha (“IFNα”) formulation, VELDONA® Pet cytoprotein dietary supplements are backed by quite a few analysis research and scientific trials, and are manufactured with world-class supplies in a extremely licensed food-grade plant. VELDONA® maintains immunity and contributes to gum and pores and skin well being, relieving allergy symptoms and decreasing stress in cats and dogs. Interferon, a sort of cytoprotein, is of course produced by human and animals. When cells are invaded by overseas particles, immune signaling molecules notify neighboring cells. Once neighboring cells obtain the interferon’s protein sign by their floor receptors, they provoke and modulate the immune system to guard felines and canines from gum and pores and skin ailments, allergy symptoms, stress-related situations, eye discomfort from infections, and weight imbalance attributable to metabolic dysfunction.
A scientific examine, sponsored by Ainos and carried out by the Agricultural Technology Research Institute in Taiwan, has demonstrated that VELDONA® helps preserve the immune programs of cats and dogs. Numerous research have reported the advantages of interferons in sustaining gum well being and pores and skin well being, relieving discomfort attributable to allergy symptoms and eye infections, soothing emotional stress, and balancing weight from metabolic dysfunction in cats and dogs. VELDONA® Pet’s mission is to keep up immunity for thousands and thousands of pets with the highest-quality merchandise.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. is a diversified medtech firm engaged in growing progressive medical applied sciences for point-of-care testing and secure and novel medical remedy for a broad vary of illness indications. In addition to its proprietary therapeutics utilizing low-dose non-injectable interferon, Ainos has additionally expanded its product portfolio to incorporate Volatile Organic Compounds (VOC) and COVID-19 POCTs. Powered by its AI Nose platform, the lead POCT candidate, Ainos Flora, is a telehealth-friendly POCT for ladies’s well being and sure frequent STIs. To study extra, go to https://www.ainos.com.
Follow Ainos on Twitter (@AinosInc) and LinkedIn to remain up-to-date.
Forward-Looking Statements
This press launch comprises “forward-looking statements” about Ainos inside the which means of the secure harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements could be recognized by means of phrases reminiscent of “anticipate,” “imagine,” “estimate,” “anticipate,” “intend,” “plan,” “predict,” “challenge,” “goal,” “future,” “doubtless,” “technique,” “foresee,” “could,” “steerage,” “potential,” “outlook,” “forecast,” “ought to,” “will” or different related phrases or phrases. Similarly, statements that describe the Company’s aims, plans or objectives are, or could also be, forward-looking statements. Forward-looking statements are primarily based solely on the Company’s present beliefs, expectations, and assumptions. Forward-looking statements are topic to inherent uncertainties, dangers, and adjustments in circumstances which are troublesome to foretell and lots of of that are exterior of the Company’s management. The Company’s precise outcomes could differ materially from these indicated within the forward-looking statements.
Important elements that might trigger the Company’s precise outcomes to vary materially from the projections, forecasts, estimates and expectations mentioned on this press launch embrace, amongst others, the cost of manufacturing and gross sales potential of the deliberate drug therapies introduced on this press launch; the Company’s dependence on revenues from the sale of COVID-19 check kits; the Company’s restricted money and historical past of losses; the Company’s capacity to attain profitability; the Company’s capacity to boost extra capital to proceed the Company’s product improvement; the flexibility to precisely predict the long run working outcomes of the Company; the flexibility to advance Ainos’ present or future product candidates by scientific trials, get hold of advertising approval and in the end commercialize any product candidates the Company develops; the flexibility to acquire and preserve regulatory approval of Ainos product candidates; delays in finishing the event and commercialization of the Company’s present and future product candidates, which may lead to elevated prices to the Company, delay or restrict the flexibility to generate income and adversely have an effect on the business, monetary situation, outcomes of operations and prospects of the Company; intense competitors and quickly advancing expertise within the Company’s business that will outpace its expertise; buyer demand for the services and products the Company develops; the impression of aggressive or various merchandise, applied sciences and pricing; disruption in analysis and improvement amenities; lawsuits and different claims by third events or investigations by varied regulatory businesses governing the Company’s operations; potential cybersecurity assaults; elevated necessities and prices associated to cybersecurity; the Company’s capacity to comprehend the advantages of third get together licensing agreements; the Company’s capacity to acquire and preserve mental property safety for Ainos product candidates; compliance with relevant legal guidelines, laws and tariffs; and the Company’s success in managing the expansion. A extra full description of those threat elements and others is included within the “Risk Factors” part of Ainos’ most recent Annual Report on Form 10-Ok and different stories filed with the U.S. Securities and Exchange Commission, lots of which dangers are past the Company’s management. In addition to the dangers described above and within the Company’s Form 10-Ok, different unknown or unpredictable elements additionally may trigger precise outcomes to vary materially from the projections, forecasts, estimates and expectations mentioned on this press launch.
The forward-looking statements made on this press launch are expressly certified of their entirety by the foregoing cautionary statements. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking assertion to mirror modified assumptions, the incidence of anticipated or unanticipated occasions or adjustments to the long run outcomes over time or in any other case, besides as required by legislation.
Investor Relations Contact
ICR, LLC
Robin Yang
Tel: +1 646-224-6971
Email: [email protected]
SOURCE: Ainos, Inc.
